We know all too well the research that supports a strong bottom-line argument for diversity and we are frustrated that more companies refuse to see what study after study confirms: women contribute heavily to the bottom line.
Pfizer and Bristol were already positioning Eliquis as being the option for patients who refuse to take warfarin, having run a clever study that compared the drug to aspirin.